Parexel Launches the Parexel Biopharm Unit to Meet the Critical Development Goals of Small and Mid-Sized Biopharmaceutical Companies
Boston, MA, July 24, 2012— PAREXEL International
Corporation (NASDAQ: PRXL), a leading global biopharmaceutical
services provider, today announced the launch of thePAREXEL
BioPharm Unit – a dedicated unit within PAREXEL focused
solely on the unique needs of small and mid-sized biopharmaceutical
companies to help them achieve their development goals.
Recent data indicates[1] that small and mid-sized companies are the
engine of the biopharmaceutical industry, with 81 percent of
ongoing development programs originating from sponsors outside of
the top 25 biopharmaceutical companies. The PAREXEL BioPharm Unit
seeks to support this critical pipeline by providing the precise
expertise, global infrastructure, operational excellence and
turn-key technologies needed to help small biopharmaceutical
companies advance their drugs through the development cycle.
Through vast experience and deep understanding of the needs of
small and emerging biopharmaceutical companies’, PAREXEL
designed this new delivery model to provide a high level of
attention and service. The goal is to provide a tailored solution
that results in accelerated development timelines, reduced cost and
a high level of quality.
“Small and mid-sized biopharmaceutical companies are truly
the genesis of innovation and have been an important part of
PAREXEL’s client base for more than 30 years,” said
Ubavka DeNoble, Vice President of BioPharm Services. “The
creation of the PAREXEL BioPharm Unit is especially important for
small pharma and biotech sponsors that have needs that are
meaningfully different from large pharma sponsors. The breadth and
depth of our expertise gives us the ability to create customized
solutions that are designed to meet the particular needs of each
client —whether the company is a small research venture, a
growing mid-sized business, or a global enterprise.”
The PAREXEL BioPharm Unit provides a senior management leader and
dedicated team offering ongoing, frequent communication and
proactive solutions. Under the dedicated team model,
PAREXEL’s BioPharm Unit provides companies the opportunity to
accelerate patient recruitment, increase the speed of study
start-up, shorten time to database lock, and improve overall
efficiency for meeting critical development milestones.
# # #
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
knowledge-based contract research, consulting, and medical
communications services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. Perceptive
Informatics, Inc., a subsidiary of PAREXEL, provides advanced
technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston,
Massachusetts, PAREXEL operates in 71 locations throughout 50
countries around the world, and has approximately 11,920 employees.
For more information about PAREXEL International visit
www.PAREXEL.com.
This release contains "forward-looking" statements regarding future
results and events, including, without limitation, statements
regarding expected financial results, future growth and customer
demand. For this purpose, any statements contained herein that are
not statements of historical fact may be deemed forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "intends," "appears,"
"estimates," "projects," "will," "would," "could," "should,"
"targets," and similar expressions are also intended to identify
forward-looking statements. The forward-looking statements in this
release involve a number of risks and uncertainties. The Company's
actual future results may differ significantly from the results
discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions and to integrate newly
acquired businesses or enter into new lines of business; the impact
on the Company's business of government regulation of the drug,
medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of exchange rate
fluctuations and other international economic, political, and other
risks. Such factors and others are discussed more fully in the
section entitled “Risk Factors” of the Company’s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2012
as filed with the SEC on May 10, 2012, which “Risk
Factors” discussion is incorporated by reference in this
press release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company’s estimates or views as of any date
subsequent to the date of this press release.
PAREXEL is a registered trademark and PAREXEL MyTrials is a
trademark of PAREXEL International Corporation and Perceptive
Informatics is a trademark of Perceptive Informatics, Inc. All
other names or marks may be registered trademarks or trademarks of
PAREXEL International Corporation, Perceptive Informatics, Inc. or
their respective owners and are hereby acknowledged.
CAITLYN KEATING
JUNIOR ASSOCIATE
PAN Communications
255 State Street DIRECT 617 502 4374
Boston, MA 02109 MOBILE 603 205 4775
pancommunications.com
BLOG www.prspeak.com
TWITTER @pancomm
FACEBOOK facebook.com/pancommunications
Posted: July 2012
